XML 29 R18.htm IDEA: XBRL DOCUMENT
v3.26.1

LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDERS | 3 Months Ended
--- | ---
Mar. 31, 2026
Earnings Per Share [Abstract] |
LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDERS | NOTE 10 - LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDERS Basic net loss per common share (“Basic EPS”) is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. All outstanding stock options and warrants for the three months ended March 31, 2026, and 2025 have been excluded from the calculation of the diluted net loss per share because all such securities are anti-dilutive for all periods presented. The following table sets forth the computation of the net loss per share for the period presented: SCHEDULE OF NET LOSS PER SHARE
|  | Three Months Ended March 31, |
|  | 2026 |  |  | 2025 |
Numerator: |  | $ |  |  |  | $ |  |
Net loss |  |  | (3,822 | ) |  |  | (1,872 | )
Dividend on Series X Preferred Stock |  |  | (623 | ) |  |  | - |
Dividend on Series H Preferred Stock |  |  | (236 | ) |  |  | - |
Deemed dividend for down round on Series H Preferred Stock (See note 7) |  |  | (16,974 | ) |  |  | - |
Deemed contribution on extinguishment of Series X Preferred Stock |  |  | 131 |  |  |  |  |
Deemed dividend on modification of Series H Preferred Stock (See note 7) |  |  | (1,097 | ) |  |  | - |
Net loss available to common stockholders |  | $ | (22,621 | ) |  | $ | (1,872 | )
ENVUE MEDICAL, INC. Notes to the Interim Condensed Consolidated Financial Statements (unaudited) (Amounts in thousands except share and per share data) The following table summarizes the Company’s securities, in common stock equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive: SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE
|  | March 31, 2026 |  |  | March 31, 2025 |
Stock options - employee and non-employee |  | $ | 4,411 |  |  | $ | 4,505 |
Warrants |  |  | 1,145,436 |  |  |  | 18,440 |
Total |  | $ | 1,149,847 |  |  | $ | 22,945 |
The diluted loss per share equals basic loss per share for the three months ended March 31, 2026, and 2025 because the Company had a net loss and the impact of the assumed exercise of stock options and the vesting of restricted stock would have been anti-dilutive.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-12 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 20 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481468/505-20-05-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration